Using Apple Watch data to predict heart failure outcomes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to determine how effectively data collected from Apple Watch can predict the heart failure status of patients experiencing decompensation. By extracting physiological data such as ECG readings, SpO2 levels, respiratory rates, and step counts, the study will utilize machine learning techniques to forecast risks of decompensation and rehospitalization. The research builds on previous findings that highlight the correlation between wearable device metrics and clinical outcomes in heart failure patients, advancing the use of multimodal data for risk assessment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* age over 17
* HFrEF with LV-EF under 41
* hospitalized for decompensated heart failure with a) nTproBNP over 1000 AND b) willing to participate AND c) at least one out of three clinical signs (edema, pleural effusion, ascites)

Exclusion Criteria:

* life expectancy under 6 months due to non-cardiac conditions
* inability to use smartwatch
* severe valvular lesions

Where it's running

• University Medical Center Goettingen
  Goettigen, Lower Saxony, Germany Recruiting

Study contacts

• Study coordinator: Soeren Sievers, Dr. med.
• Email: soeren.sievers@med.uni-goettingen.de
• Phone: 00495513965044

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing Aortix Device to Diuretics for Acute Heart Failure

  This study is testing whether the Aortix device can help people with acute heart failure who aren't responding to diuretics feel better compared to standard treatment.

  Recruiting at 33 sites Procyrion · Phoenix, Arizona and 49 other locations · NCT05677100

• Stepwise withdrawal of ARNI and SGLT2i in HF with normalized ejection fraction

  This trial tests whether gradually stopping ARNI and SGLT2i is safe for people whose heart function has recovered after fixing a reversible heart‑disease cause.

  Recruiting Phase 4 Keimyung University Dongsan Medical Center · Daegu, Daegu and 4 other locations · NCT07631156

• Using urine sodium to guide IV diuretic dosing for hospitalized acute heart failure

  This trial will test whether increasing IV diuretic doses to reach higher urine sodium levels helps hospitalized adults with acute decompensated heart failure remove more salt and fluid and have fewer readmissions.

  Recruiting Phase 4 Lakeland Regional Health Systems, Inc. · Lakeland, Florida · NCT07263035

• Pulmonary Artery Denervation for a specific type of heart and lung pressure problem

  This study tests whether the Enhancor System can safely and effectively help patients with combined pre- and post-capillary pulmonary hypertension due to left heart disease when added to standard therapy.

  Recruiting at 18 sites Pulnovo Medical, Inc. · Tucson, Arizona and 18 other locations · NCT07214376

• Using omecamtiv mecarbil to treat chronic heart failure with severely reduced ejection fraction

  This study is testing if a new drug called omecamtiv mecarbil can help people with severe chronic heart failure live longer and avoid serious heart problems.

  Recruiting at 205 sites Phase 3 Cytokinetics · Alexander City, Alabama and 212 other locations · NCT06736574

• Using intravenous albumin to prevent worsening kidney function in heart failure patients

  This study is testing if giving heart failure patients a special protein through an IV can help their kidneys work better when they're also having liver problems.

  Recruiting Phase 3 Democritus University of Thrace · Alexandroupoli, Evros · NCT06630923

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.